Patients aged <1 year with VGLL2, SBF, TEAD1, and NCOA2 gene fusions had a better prognosis, whereas patients with a MYOD1 gene mutation demonstrated stronger tumor aggression and higher mortality, regardless of age. Here, VGLL2 is linked to neoplasm.